Atezolizumab + bevacizumab shows long-term benefits over sorafenib for unresectable HCC January 6, 2022Hepatocellular Carcinoma
No survival benefits with first-line nivolumab vs sorafenib in advanced HCCJanuary 6, 2022Hepatocellular Carcinoma
Prostate cancer: Preoperative mpMRI PI-RAD score is linked to upstagingDecember 18, 2021Prostate Cancer
Low-grade prostate cancer: Secondary treatment rates slightly higher with delayed surgeryDecember 18, 2021Prostate Cancer
Prostate cancer: Positive targeted cores increase upgradation risk in active surveillanceDecember 18, 2021Prostate Cancer
Prostate cancer: Grade group 2 is associated with higher treatment rateDecember 18, 2021Prostate Cancer
Prostate cancer: Patient- and surgeon-level variation in postsurgery sexual function outcomesDecember 18, 2021Prostate Cancer
